Phase I Study to Determine the Safety, Maximum Tolerated Dose, PK of BAY 43-9006 in Repeated Cycles of 18 Days On/3 Days Off in Combination With Paclitaxel and Carboplatin Chemotherapy in Patients With Advanced, Refractory Solid Tumors.
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Sorafenib (Primary) ; Carboplatin; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bayer
Most Recent Events
- 25 Jul 2009 New trial record